ERYTHROMELALGIA NEWS!
Convergence Pharmaceuticals have announced their phase 2a study of BIIB-074 in the treatment of erythromelalgia (Enrollment by invitation only) A Phase 2a Study of BIIB-074 in the Treatment of Erythromelalgia
ERYTHROMELALGIA NEWS!
Convergence Pharmaceuticals have announced their phase 2a study of BIIB-074 in the treatment of erythromelalgia (Enrollment by invitation only) A Phase 2a Study of BIIB-074 in the Treatment of Erythromelalgia